IRIS Accounts Production v26.1.10.61 14715068 Board of Directors Board of Directors 1.4.25 31.3.26 31.3.26 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh147150682025-03-31147150682026-03-31147150682025-04-012026-03-31147150682024-03-31147150682024-04-012025-03-31147150682025-03-3114715068ns15:EnglandWales2025-04-012026-03-3114715068ns14:PoundSterling2025-04-012026-03-3114715068ns10:Director12025-04-012026-03-3114715068ns10:Director22025-04-012026-03-3114715068ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3114715068ns10:SmallEntities2025-04-012026-03-3114715068ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3114715068ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3114715068ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3114715068ns10:FullAccounts2025-04-012026-03-311471506812025-04-012026-03-3114715068ns10:RegisteredOffice2025-04-012026-03-3114715068ns5:CurrentFinancialInstruments2026-03-3114715068ns5:CurrentFinancialInstruments2025-03-3114715068ns5:Non-currentFinancialInstruments2026-03-3114715068ns5:Non-currentFinancialInstruments2025-03-3114715068ns5:ShareCapital2026-03-3114715068ns5:ShareCapital2025-03-3114715068ns5:RetainedEarningsAccumulatedLosses2026-03-3114715068ns5:RetainedEarningsAccumulatedLosses2025-03-3114715068ns5:NetGoodwill2025-04-012026-03-3114715068ns5:NetGoodwill2025-03-3114715068ns5:NetGoodwill2026-03-3114715068ns5:NetGoodwill2025-03-3114715068ns5:LandBuildings2025-03-3114715068ns5:PlantMachinery2025-03-3114715068ns5:FurnitureFittings2025-03-3114715068ns5:LandBuildings2025-04-012026-03-3114715068ns5:PlantMachinery2025-04-012026-03-3114715068ns5:FurnitureFittings2025-04-012026-03-3114715068ns5:LandBuildings2026-03-3114715068ns5:PlantMachinery2026-03-3114715068ns5:FurnitureFittings2026-03-3114715068ns5:LandBuildings2025-03-3114715068ns5:PlantMachinery2025-03-3114715068ns5:FurnitureFittings2025-03-3114715068ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3114715068ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3114715068ns5:Non-currentFinancialInstruments2025-04-012026-03-3114715068ns5:RetainedEarningsAccumulatedLosses2025-03-3114715068ns5:RetainedEarningsAccumulatedLosses2025-04-012026-03-31
REGISTERED NUMBER: 14715068 (England and Wales)









Unaudited Financial Statements

for the Year Ended 31 March 2026

for

A&R Pharma Ltd

A&R Pharma Ltd (Registered number: 14715068)






Contents of the Financial Statements
for the Year Ended 31 March 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


A&R Pharma Ltd

Company Information
for the Year Ended 31 March 2026







DIRECTORS: J Lloyd-Jones
Miss A L Matthews





REGISTERED OFFICE: P WJohn & Co
Parkview
23 Wadham Street
Weston-super-Mare
Somerset
BS23 1JZ





REGISTERED NUMBER: 14715068 (England and Wales)





ACCOUNTANTS: P W John & Co
Parkview
23 Wadham Street
Weston-super-Mare
Somerset
BS23 1JZ

A&R Pharma Ltd (Registered number: 14715068)

Balance Sheet
31 March 2026

31.3.26 31.3.25
Notes £    £   
FIXED ASSETS
Intangible assets 4 105,000 119,000
Tangible assets 5 62,030 59,106
167,030 178,106

CURRENT ASSETS
Stocks 37,500 28,500
Debtors 6 109,224 110,238
Cash at bank 48,361 31,816
195,085 170,554
CREDITORS
Amounts falling due within one year 7 (126,977 ) (76,989 )
NET CURRENT ASSETS 68,108 93,565
TOTAL ASSETS LESS CURRENT
LIABILITIES

235,138

271,671

CREDITORS
Amounts falling due after more than one
year

8

(117,667

)

(213,399

)
NET ASSETS 117,471 58,272

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 9 116,471 57,272
117,471 58,272

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

A&R Pharma Ltd (Registered number: 14715068)

Balance Sheet - continued
31 March 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 June 2026 and were signed on its behalf by:




Miss A L Matthews - Director



J Lloyd-Jones - Director


A&R Pharma Ltd (Registered number: 14715068)

Notes to the Financial Statements
for the Year Ended 31 March 2026

1. STATUTORY INFORMATION

A&R Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Due to the nature of pharmacy revenue, there is an element of estimation involved. There is also some variability in the initial recognition of pharmacy revenue, which is settled on the actual receipt of funds.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2023, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Plant and machinery - 20% on cost
Fixtures and fittings - 20% on cost
Freehold buildings - 2% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
The tax currently payable is based on taxable profit for the year.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2025 - 5 ) .

A&R Pharma Ltd (Registered number: 14715068)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2025
and 31 March 2026 140,000
AMORTISATION
At 1 April 2025 21,000
Charge for year 14,000
At 31 March 2026 35,000
NET BOOK VALUE
At 31 March 2026 105,000
At 31 March 2025 119,000

5. TANGIBLE FIXED ASSETS
Freehold Fixtures
land and Plant and and
building machinery fittings Totals
£    £    £    £   
COST
At 1 April 2025 49,356 - 15,000 64,356
Additions - 8,639 - 8,639
At 31 March 2026 49,356 8,639 15,000 72,995
DEPRECIATION
At 1 April 2025 750 - 4,500 5,250
Charge for year 987 1,728 3,000 5,715
At 31 March 2026 1,737 1,728 7,500 10,965
NET BOOK VALUE
At 31 March 2026 47,619 6,911 7,500 62,030
At 31 March 2025 48,606 - 10,500 59,106

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade debtors 91,340 88,885
Other debtors 17,884 21,353
109,224 110,238

A&R Pharma Ltd (Registered number: 14715068)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade creditors 97,708 44,163
Taxation and social security 26,769 30,326
Other creditors 2,500 2,500
126,977 76,989

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.26 31.3.25
£    £   
Other creditors 117,667 213,399

Other creditors relates to loans from related parties.

9. RESERVES
Retained
earnings
£   

At 1 April 2025 57,272
Profit for the year 75,299
Dividends (16,100 )
At 31 March 2026 116,471